UroGen published 24‑month durability data for its drug ZUSDURI in The Journal of Urology on March 30, 2026. The study, derived from the ENVISION trial, reports a 72.2% probability that patients who achieved a complete response remain event‑free at 24 months, a 79.6% complete response rate at three months, and a median follow‑up of 23.7 months.
ZUSDURI is the first and only FDA‑approved therapy for low‑grade intermediate‑risk non‑muscle invasive bladder cancer (LG‑IR‑NMIBC). The durability data reinforce its clinical value and could shift the treatment paradigm from repeated transurethral resection of bladder tumor (TURBT) procedures to a single six‑week induction course.
The findings support broader market adoption by increasing physician confidence and expanding the addressable patient population. An estimated 59,000 U.S. patients experience recurrence of LG‑IR‑NMIBC each year, and the durable response data suggest ZUSDURI could reduce the need for repeated surgeries, especially for elderly patients with comorbidities.
Sandip Prasad, M.D., M.Phil., Principal Investigator of the ENVISION trial, said, “The publication of these long‑term data in The Journal of Urology provides important peer‑reviewed validation of the durability of ZUSDURI treatment observed in the ENVISION trial. For patients who achieved a complete response, the likelihood of remaining event‑free through two years was substantial, underscoring the potential of ZUSDURI to change the long‑term management of this highly recurrent disease with a six‑week induction treatment alone without maintenance.”
Mark Schoenberg, Chief Medical Officer, added, “Now that the 24‑month duration of response data from ENVISION are published in a leading urology journal, we’re seeing even stronger validation of ZUSDURI’s clinical impact. As the first and only approved treatment for recurrent LG‑IR‑NMIBC, ZUSDURI gives patients a real chance at meaningful, recurrence‑free periods. These results suggest we may finally be able to break the long‑standing cycle of repeated recurrences and surgeries that has defined care for patients with recurrent LG‑IR‑NMIBC.”
The publication adds to a series of positive clinical data releases that have reinforced UroGen’s position in the bladder cancer market and support continued confidence in the company’s therapeutic portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.